Raport bieżący nr 6/2021
Art. 17 ust. 1 MAR - informacje poufne.
The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”), today announced that that it has begun selling its CompuFlo® Epidural Instrument and related disposables to the University Hospital of Würzburg, one of the leading national hospitals in Germany.
Dr. Peter Kranke, Professor of Anesthesia in the Department of Anesthesia and Critical Care, at the University Hospital of Würzburg, Germany, and the Würzburg Medical School, stated that based on the high accidental dural punctures with the loss of resistance that Dawkins found and the own published results on the CompuFlo, the team of University Hospital of Würzburg was impressed with Milestone’s CompuFlo Epidural Instrument. Introduction of the CompuFlo is an important step towards enhancing the safety of epidural analgesia and anesthesia. Based on the latest literature, the incidence of accidental dural puncture is considered high by modern standards, which is attributable to the standard loss of resistance technique used today. CompuFlo provides an attractive alternative as its addresses “false-positives” and subsequent suboptimal analgesia. CompuFlo also holds significant potential given its ability to reduce complication rates.
The Board of Directors of the Company appreciates the decision of the University Hospital of Würzburg, in association with Dr. Kranke and his team, to purchase CompuFlo Epidural System. Dr. Kranke is a premier anesthesiologist and key opinion leader in the area of safe delivery of anesthesia and analgesia. The Board of Directors of the Issuer believes this initial order by a leading European hospital and medical teaching institute is further validation that the technology provides a level of safety and efficiency not available for medical professionals using conventional syringes. The Board of Directors of the Company looks forward to further expanding the global rollout strategy of the CompuFlo Epidural System and is working closely with other hospitals across Europe and North America.
The Board of Directors of the Issuer states that this agreement illustrates the positive response for the CompuFlo Epidural Instrument. In addition to hiring more salespeople and expanding the sales funnel, advanced trials are already underway that the Board of Directors of the Issuer believes will convert to commercial orders. The Board of Directors of the Company is now aggressively accelerating the commercialization efforts in both domestic and global markets as the Issuer is pursuing the goal to become the new standard of care.
|PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ|
|Data||Imię i Nazwisko||Stanowisko/Funkcja||Podpis|
|2021-02-23||Joseph D'Agostino||Chief Financial Officer||Joseph D'Agostino|